The first 1000 cases notified to the National Childhood Encephalopathy Study were analysed. The diagnoses included encephalitis/encephalopathy, prolonged convulsions, infantile spasms, and Reye's syndrome. Eightyeight of the children had had a recent infectious disease, including 19 with pertussis.
Introduction
We report findings from the first 1000 cases notified during an investigation of serious neurological illnesses in early childhood and their relation to immunisation with vaccine containing pertussis antigen.
Although there have been reports of neurological illness after pertussis immunisation since 1933,1 none has been based on established epidemiological methods using relevant controls.
The inconclusive nature of this evidence has resulted in much debate in the media, particularly in Britain,2 3 Table III lists the numbers of children with a history of certain infectious diseases within four weeks before admission to hospital. The diseases were selected because they are sometimes associated with postinfectious encephalitis. In each of categories IA and IB some 100/ of children had recently had one of the infections. Seventeen previously normal children had had recent pertussis infection. A year later one of these had died, one had severe neurological sequelae, and one had mild speech delay. The remaining 14 were normal. CLINICAL DIAGNOSIS AND LATE OUTCOME OF VACCINE-ASSOCIATED CASES Diphtheria, tetanus, and pertussis vaccine--Thirty-five children had been immunised with the triple vaccine within seven days of onset of the neurological illniess. Twwenty were in category IA (normalnormal). Twelve had convulsions alone, four had encephalopathy, three had infantile spasms, and one had acute infantile hemiplegia. At final follow-up at least one year later 18 were normal, one had minor delay in speech development, and one had a major delay in global development. Of the 12 children in category IB, two had prolonged convulsions, six had encephalitis/encephalopathy, three had infantile spasms, and one had Reye's syndrome. At final follow-up three children were regarded as normal, seven showed varying degrees of developmental retardation, and two had died. Two children had an alternative explanation for their neurological condition. The three children in category II had prolonged convulsions. One child had a history of birth asphyxia and cerebral palsy, another had agenesis of the corpus callosum, and the third had shown retarded development from birth. Table IX gives the clinical details of all 11 children reported as abnormal one year or more after immunisation with the triple vaccine. It must be emphasised that the abnormalities in these children cannot necessarily be ascribed to pertussis immunisation.
level. These calculations were made without excluding cases with evidence of other possible causes, such as viral illnesses or late-presenting congenital abnormalities such as tuberous sclerosis, and thus may overestimate the risks. We conclude that serious neurological reactions after immunisation with the triple vaccine are very rare and most of the vaccine-associated cases showed no evidence of residual damage one year later.
CAUSE VERSUS ASSOCIATION
Finding a statistically significant association between two independent variables at the 5% level does not necessarily imply that one event caused the other. Other evidence which would support a causal association would be that the illnesses are (a) clinically distinctive, (b) restricted to immunised children, (c) closely related in time to immunisation, (d) associated with a biologically plausible pathogenesis, and (e) without alternative explanation. In the case of the triple vaccine and serious neurological illnesses only some of these criteria were satisfied.
The range of neurological illnesses found in cascs associated with the triple vaccine was clinically indistinguishable fromii thltl occurring in unimmunised children or in cases associated with the diphtheria and tetanus vaccine. This finding does iot support Stewart's concept of a "pertussis reaction syndrome."3 A close time relation was found between the onset of Illncss and preceding immunisation with diphtheria, tetanus, and pertussis vaccine. The mechanism for pertussis-vaccine-associated neurological disease remains obscure: it may either be caused by a direct neurotoxic effect or be mediated indirectly via immune mechanisms.8 Finally, an alternative aetiology for the neurological illness was suggested in some of the cases.
ATTRIBUTABLE RISK
The attributable risk9 is that part of the incidence of a disease which can be attributed to a particular causal agent and represents the difference between the incidence of the condition (serious neurological disorders) in exposed (immunised) subjects and that in non-exposed (unimmunised) subjects.-It can usually be calculated only from a cohort study. The present study, however, covered an entire national population, so that the number of serious neurological illnesses notified should in theory represent the total incidence of such conditions in the population. By making further assumptions about the 1598 exposure of the population to immunisation, estimates of attributable risk may be calculated. Nevertheless, because of the broad nature of these assumptions and the wide confidence limits the derived risk figures must be interpreted with extreme caution and cannot be regarded as precise measures.
The estimated attributable risk of serious neurological disorders occurring within seven days after immunisation with diphtheria, tetanus, and pertussis vaccine in previously normal children irrespective of outcome is one in 110000 injections (95% confidence limits, one in 360 000 to one in 44 000). The corresponding rate for previously normal children with neurological sequelae persistent one year later is one in 310 000 injections (95% confidence limits, one in 5 310 000 to one in 54 000). These estimates include all vaccine-associated cases without excluding any with a possible alternative explanation.
The risk figures derived by the study must be set against the dangers of pertussis disease. Though 17 previously normal children had had pertussis, of whom three had sequelae, the age range covered by the study does not include the complete incidence of the disease. If, however, estimates of the risks of pertussis can be obtained from other sources, those in conjunction with the present results should allow a valid judgment to be made about pertussis immunisation policy. (Accepted 30 March 1981) What investigations are advised for an 11-year-old apparently normal boy who is greatly undersized ? His parents and sisters are of normal size.
A thorough physical examination should show whether this boy is otherwise in good health. Particular pitfalls to be avoided are occult gastrointestinal disease, undertreated asthma, and psychological problems. These will all tend to make the boy strikingly thin. If he is otherwise normal no investigations should be done until he has been shown not to be growing at a normal rate. If two measurements made by the same person on the same equipment show that the height has not increased by at least 2 cm in a six-month period an endocrine (or other) abnormality should be considered. This will probably entail investigation in hospital with a view to excluding pituitary problems, hypothyroidism, and other causes of short stature with a low-growth velocity.
If the boy is growing at a normal rate his history may explain his present size. Nevertheless, nothing can now be done to improve his final height, which will be predicted by measuring the skeletal maturity, which will indicate how long growth will continue. Measurement of skeletal maturity does not generally help in making an organic diagnosis. If the bone age is greatly delayed and growth will continue for a very long time it may be permissible to contemplate treatment to shorten the growing period, but this will not increase final height. Such treatment with androgenic hormones can lead to a reduction in adult height achieved (if large doses are used) and the decision to treat is difficult.
The combination of ephedrine, theophylline, and phenobarbitone is used for treating asthma. Does this combination have any particular side effects that the patient should be warned about ?
In general, prescription of medicines containing more than one drug should be avoided. An increased number of adverse effects are likely, and the causative drug may be difficult to identify or even be overoverlooked if the medicine is not recognised to contain several drugs. Also, there is a greater likelihood of interactions with other drugs taken by the patient. Theophylline is an effective bronchodilator and the oral dose should be titrated to give a plasma concentration of 10-20 mg/l for maximum therapeutic effect. Since some patients require large oral doses to achieve this, considerable ingestion of the other drugs, phenobarbitone and ephedrine, will occur. As a result the patient may experience drowsiness related to the phenobarbitone, and urinary retention, cardiac arrhythmias, psychoses, and nasal obstruction due to the sympathomimetic drug ephedrine. Phenobarbitone is a potent inducer of hepatic enzymes but is thought to increase the metabolism of theophylline-that is, diminish the therapeutic effect at given doses-in only a few patients. The phenobarbitone, however, may interfere with the plasma binding and metabolism of other drugs given at the same time. If the therapeutic plasma range for theophylline is exceeded toxic effects may be seen-for instance, agitation, confusion, convulsions, nausea, vomiting, and other gastrointestinal effects.
A patient with severe rheumatoid arthritis fractured her right tibia and fibula after a relatively slight injury. Radiography confirmed the diagnosis but also showed pronounced osteoporosis of the bones. Should this osteoporosis be treated with, say, calcium lactate and vitamin D or is there any other treatment ?
Rheumatoid arthritis is associated with osteoporosis on three counts. Firstly, the disease itself probably leads to mild bone loss, this effect being most pronounced in postmenopausal women; secondly, prolonged steroid treatment leads to pronounced osteoporosis in all age groups, and, finally, bed rest is associated with bone loss. Furthermore, many arthritic patients develop vitamin D deficiency and osteomalacia because they are not exposed to much sunlight.' In the housebound, particularly, vitamin D replenishment in "physiological" doses-for example, 500 IU daily as a calcium and vitamin D tablet BPC that must be chewed-may help to avoid the tragedy of a major fracture. Steroids endanger the skeleton but if their administration is unavoidable they should be given on alternate days. In postmenopausal women the diet should contain at least 1-2 g elemental calcium, and further supplementation of calcium with or without low-dose hormone-replacement therapy-for example, 5 
